References
- LeRoy E C. Pathogenesis of scleroderma (systemic sclerosis). J Invest Dermatol 1982; 79(Suppl 1)87–9
- Postlethwaite A E, Kang A H. Pathogenesis of progressive systemic sclerosis. J Lab Clin Med 1984; 103: 506–10
- Fleischmajer R, Perlish J S, Reeves J RT. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977; 20: 975–84
- Haynes D C, Gershwin M E. The immunopathology of progressive systemic sclerosis (PSS). Semin Arthritis Rheum 1982; 11: 331–51
- Furst D E, Hillis S, Lachenbruch P A, Paulus H E, Miller B E, Clements P J. Preliminary results of a double-blind, parallel, randomized trial of chlorambucil vs. placebo in progressive systemic sclerosis (PSS). Arthritis Rheum 1986, suppl 4: 29
- Dau P C, Kahleh M B, Sagebiel R W. Plasmapheresis and immunosuppressive drug therapy in scleroderma. Arthritis Rheum 1981; 24: 1128–36
- Masi A T, Rodnan G P, Medsger T A, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90
- Steen V D, Medsger T A, Rodnan G P. D-penicillamine therapy in progressive systemic sclerosis (scleroderma). Ann Int Med 1982; 97: 652–S
- Åkesson A, Forsberg L, Hederström E, Wollheim F. Ultrasound examination of skin thickness in patients with progressive systemic sclerosis (scleroderma). Acta Radiol 1986; 27: 91–4
- Åkesson A, Åkesson B, Gustafson T, Wollheim F. Gastrointestinal function in patients with progressive systemic sclerosis. Clin Rheumatol 1985; 4: 441–8
- Åkesson A, Gustafson T, Wollheim F, Brismar J. Esophageal dysfunction and radionuclide transit in progressive systemic sclerosis. Scand J Rheumatol 1987; 16: 291–9
- Jonson B. A method for determination of pulmonary elastic recoil and resistance at a regulated flow rate. Scand J Clin Lab Invest 1969; 24: 115–25
- Berglund E, Birath G, Bjure J, et al. Spirometric studies in normal subjects. I. Forced expirograms in subjects between 7 and 70 years of age. Acta Med Scand 1963; 173: 185–92
- Pahlm O, Jonson B, Werner O, et al. Computer-aided visual analyses of long term ECG-recordings. Eur Heart J 1981; 2: 487–98
- Brochner-Mortensen J. A simple method for determination of glomerular filtration rate. Scand J Clin Lab Invest 1972; 30: 271–4
- Rodnan G P. Progressive systemic sclerosis: Clinical features and pathogenesis of cutaneous involvement (scleroderma). Clin Rheum Dis 1979; 5: 49–79
- Garrett J M, Winkelmann R K, Schlegel J F, Code C F. Esophageal deterioration in scleroderma. Mayo Clin Proc 1971; 46: 92–6
- Blom-Bülow B, Öberg K, Wollheim F A, et al. Cyclofenil versus placebo in progressive systemic sclerosis. Acta Med Scand 1981; 210: 419–28
- Kaplan R A, Ward D M. Plasmapheresis plus steroid and cytotoxic therapy in scleroderma. Arthritis Rheum 1986; 29(suppl)24
- Medsger T A, Masi A T, Rodnan G P, Benedek T G, Robinson H. Survival with systemic sclerosis. Ann Int Med 1971; 75: 369–76
- Owens G R, Paradis I L, Gryzan S, et al. Role of inflammation in the lung disease of systemic sclerosis: Comparison with idiopathic pulmonary fibrosis. J Lab Clin Med 1986; 107: 253–60
- Silver R M, Metcalf J F, LeRoy E C. Interstitial lung disease in scleroderma. Immune complexes in sera and bronchoalveolar lavage fluid. Arthritis Rheum 1986; 29: 525–31
- Schneider P D, Wise R A, Hochberg M C, Wigley F M. Serial pulmonary function in systemic sclerosis. Am J Med 1982; 73: 385–94
- Follansbee W P, Curtiss E I, Rahko P S, et al. The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. Am J Med 1985; 79: 183–92
- MacKenzie A H. Prolonged alkylating drug therapy is beneficial in systemic scleroderma (PSS). Arthritis Rheum 1970; 13: 334
- McCune M A, Winkelmann R K, Osmundson P J, Pineda A A. Plasma exchange: A controlled study of the effect in patients with Raynaud's phenomenon and scleroderma. J Clin Apheresis 1983; 1: 206–14